TipRanks (Thu, 18-Dec 6:50 AM ET)
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
PRNewswire (Tue, 9-Dec 11:58 AM ET)
Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference
Business Wire (Tue, 25-Nov 7:00 AM ET)
Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
Business Wire (Thu, 6-Nov 4:00 PM ET)
Globe Newswire (Thu, 23-Oct 6:03 PM ET)
Market Chameleon (Tue, 14-Oct 7:18 AM ET)
Business Wire (Tue, 14-Oct 7:00 AM ET)
Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Fri, 10-Oct 4:00 PM ET)
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
Rocket Pharmaceuticals trades on the NASDAQ stock market under the symbol RCKT.
As of December 23, 2025, RCKT stock price declined to $3.45 with 1,577,322 million shares trading.
RCKT has a beta of 1.68, meaning it tends to be more sensitive to market movements. RCKT has a correlation of 0.06 to the broad based SPY ETF.
RCKT has a market cap of $373.37 million. This is considered a Small Cap stock.
Last quarter Rocket Pharmaceuticals reported $0 in Revenue and -$.45 earnings per share. This fell short of revenue expectation by $-250,000 and exceeded earnings estimates by $.05.
In the last 3 years, RCKT traded as high as $32.53 and as low as $2.19.
The top ETF exchange traded funds that RCKT belongs to (by Net Assets): VTI, IWM, VXF, IBB, IWN.
RCKT has underperformed the market in the last year with a price return of -70.2% while the SPY ETF gained +17.6%. However, in the short term, RCKT had mixed performance relative to the market. It has outperformed in the last 3 months, returning +8.5% vs +3.5% return in SPY. But in the last 2 weeks, RCKT shares have been beat by the market, returning -1.4% compared to an SPY return of +0.9%.
RCKT support price is $3.37 and resistance is $3.69 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RCKT shares will trade within this expected range on the day.
